The effect of Glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity

Aaron S Kelly, Kyle Rudser, Brandon M Nathan, Claudia K Fox, Andrea M. Metzig, Brandon Coombes, Angela K. Fitch, Eric M Bomberg, M. Jennifer Abuzzahab

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Importance: Medical treatment options for pediatric obesity remain limited. Glucagon-like peptide-1 (GLP-1) receptor agonists induce weight loss by suppressing appetite and increasing satiety, but few studies have evaluated this therapy as a treatment for obesity. Objective: To evaluate the effects of exenatide on body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) and cardiometabolic risk factors in adolescents with severe obesity. Design: Three-month, randomized, double-blind, placebocontrolled, multicenter clinical trial followed by a 3-month open-label extension. Setting: An academic medical center and an outpatient pediatric endocrinology clinic. Patients: A total of 26 adolescents (12-19 years of age) with severe obesity (BMI≥1.2 times the 95th percentile or BMI≥35). Intervention: All patients received lifestyle modification counseling and were equally randomized to exenatide or placebo injection, twice per day. Main Outcome Measures: The primary end point was the mean percent change in BMI measured at baseline and 3 months. Secondary end points included absolute change in BMI, body weight, body fat, blood pressure, hemoglobin A1c, fasting glucose, fasting insulin, and lipids at 3 months. Results: Twenty-two patients completed the trial. Exenatide elicited a greater reduction in percent change in BMI compared with placebo (-2.70% [95% CI,-5.02% to -0.37%]; P=.03). Similar findings were observed for absolute change in BMI (-1.13 [95% CI,-2.03 to-0.24]; P=.02) and body weight (-3.26 kg [95% CI, -5.87 to -0.66 kg]; P=.02). Although not reaching the level of statistical significance, reduction in systolic blood pressure was observed with exenatide. During the openlabel extension, BMI was further reduced in those initially randomized to exenatide (cumulative BMI reduction of 4%). Conclusions and Relevance: These results provide preliminary evidence supporting the feasibility, safety, and efficacy of GLP-1 receptor agonist therapy for the treatment of severe obesity in adolescents.

Original languageEnglish (US)
Pages (from-to)355-360
Number of pages6
JournalJAMA Pediatrics
Volume167
Issue number4
DOIs
StatePublished - Apr 1 2013

Fingerprint

Morbid Obesity
Body Mass Index
Blood Pressure
Fasting
Placebos
Body Weight
Therapeutics
Endocrinology
Pediatric Obesity
Appetite
Multicenter Studies
Adipose Tissue
Life Style
Counseling
Weight Loss
Hemoglobins
Outpatients
Obesity
Outcome Assessment (Health Care)
Glucagon-Like Peptide-1 Receptor

Cite this

The effect of Glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity. / Kelly, Aaron S; Rudser, Kyle; Nathan, Brandon M; Fox, Claudia K; Metzig, Andrea M.; Coombes, Brandon; Fitch, Angela K.; Bomberg, Eric M; Abuzzahab, M. Jennifer.

In: JAMA Pediatrics, Vol. 167, No. 4, 01.04.2013, p. 355-360.

Research output: Contribution to journalArticle

@article{4b6f06f2b61444f49fd2c4298879a1e8,
title = "The effect of Glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity",
abstract = "Importance: Medical treatment options for pediatric obesity remain limited. Glucagon-like peptide-1 (GLP-1) receptor agonists induce weight loss by suppressing appetite and increasing satiety, but few studies have evaluated this therapy as a treatment for obesity. Objective: To evaluate the effects of exenatide on body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) and cardiometabolic risk factors in adolescents with severe obesity. Design: Three-month, randomized, double-blind, placebocontrolled, multicenter clinical trial followed by a 3-month open-label extension. Setting: An academic medical center and an outpatient pediatric endocrinology clinic. Patients: A total of 26 adolescents (12-19 years of age) with severe obesity (BMI≥1.2 times the 95th percentile or BMI≥35). Intervention: All patients received lifestyle modification counseling and were equally randomized to exenatide or placebo injection, twice per day. Main Outcome Measures: The primary end point was the mean percent change in BMI measured at baseline and 3 months. Secondary end points included absolute change in BMI, body weight, body fat, blood pressure, hemoglobin A1c, fasting glucose, fasting insulin, and lipids at 3 months. Results: Twenty-two patients completed the trial. Exenatide elicited a greater reduction in percent change in BMI compared with placebo (-2.70{\%} [95{\%} CI,-5.02{\%} to -0.37{\%}]; P=.03). Similar findings were observed for absolute change in BMI (-1.13 [95{\%} CI,-2.03 to-0.24]; P=.02) and body weight (-3.26 kg [95{\%} CI, -5.87 to -0.66 kg]; P=.02). Although not reaching the level of statistical significance, reduction in systolic blood pressure was observed with exenatide. During the openlabel extension, BMI was further reduced in those initially randomized to exenatide (cumulative BMI reduction of 4{\%}). Conclusions and Relevance: These results provide preliminary evidence supporting the feasibility, safety, and efficacy of GLP-1 receptor agonist therapy for the treatment of severe obesity in adolescents.",
author = "Kelly, {Aaron S} and Kyle Rudser and Nathan, {Brandon M} and Fox, {Claudia K} and Metzig, {Andrea M.} and Brandon Coombes and Fitch, {Angela K.} and Bomberg, {Eric M} and Abuzzahab, {M. Jennifer}",
year = "2013",
month = "4",
day = "1",
doi = "10.1001/jamapediatrics.2013.1045",
language = "English (US)",
volume = "167",
pages = "355--360",
journal = "JAMA Pediatrics",
issn = "2168-6203",
publisher = "American Medical Association",
number = "4",

}

TY - JOUR

T1 - The effect of Glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity

AU - Kelly, Aaron S

AU - Rudser, Kyle

AU - Nathan, Brandon M

AU - Fox, Claudia K

AU - Metzig, Andrea M.

AU - Coombes, Brandon

AU - Fitch, Angela K.

AU - Bomberg, Eric M

AU - Abuzzahab, M. Jennifer

PY - 2013/4/1

Y1 - 2013/4/1

N2 - Importance: Medical treatment options for pediatric obesity remain limited. Glucagon-like peptide-1 (GLP-1) receptor agonists induce weight loss by suppressing appetite and increasing satiety, but few studies have evaluated this therapy as a treatment for obesity. Objective: To evaluate the effects of exenatide on body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) and cardiometabolic risk factors in adolescents with severe obesity. Design: Three-month, randomized, double-blind, placebocontrolled, multicenter clinical trial followed by a 3-month open-label extension. Setting: An academic medical center and an outpatient pediatric endocrinology clinic. Patients: A total of 26 adolescents (12-19 years of age) with severe obesity (BMI≥1.2 times the 95th percentile or BMI≥35). Intervention: All patients received lifestyle modification counseling and were equally randomized to exenatide or placebo injection, twice per day. Main Outcome Measures: The primary end point was the mean percent change in BMI measured at baseline and 3 months. Secondary end points included absolute change in BMI, body weight, body fat, blood pressure, hemoglobin A1c, fasting glucose, fasting insulin, and lipids at 3 months. Results: Twenty-two patients completed the trial. Exenatide elicited a greater reduction in percent change in BMI compared with placebo (-2.70% [95% CI,-5.02% to -0.37%]; P=.03). Similar findings were observed for absolute change in BMI (-1.13 [95% CI,-2.03 to-0.24]; P=.02) and body weight (-3.26 kg [95% CI, -5.87 to -0.66 kg]; P=.02). Although not reaching the level of statistical significance, reduction in systolic blood pressure was observed with exenatide. During the openlabel extension, BMI was further reduced in those initially randomized to exenatide (cumulative BMI reduction of 4%). Conclusions and Relevance: These results provide preliminary evidence supporting the feasibility, safety, and efficacy of GLP-1 receptor agonist therapy for the treatment of severe obesity in adolescents.

AB - Importance: Medical treatment options for pediatric obesity remain limited. Glucagon-like peptide-1 (GLP-1) receptor agonists induce weight loss by suppressing appetite and increasing satiety, but few studies have evaluated this therapy as a treatment for obesity. Objective: To evaluate the effects of exenatide on body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) and cardiometabolic risk factors in adolescents with severe obesity. Design: Three-month, randomized, double-blind, placebocontrolled, multicenter clinical trial followed by a 3-month open-label extension. Setting: An academic medical center and an outpatient pediatric endocrinology clinic. Patients: A total of 26 adolescents (12-19 years of age) with severe obesity (BMI≥1.2 times the 95th percentile or BMI≥35). Intervention: All patients received lifestyle modification counseling and were equally randomized to exenatide or placebo injection, twice per day. Main Outcome Measures: The primary end point was the mean percent change in BMI measured at baseline and 3 months. Secondary end points included absolute change in BMI, body weight, body fat, blood pressure, hemoglobin A1c, fasting glucose, fasting insulin, and lipids at 3 months. Results: Twenty-two patients completed the trial. Exenatide elicited a greater reduction in percent change in BMI compared with placebo (-2.70% [95% CI,-5.02% to -0.37%]; P=.03). Similar findings were observed for absolute change in BMI (-1.13 [95% CI,-2.03 to-0.24]; P=.02) and body weight (-3.26 kg [95% CI, -5.87 to -0.66 kg]; P=.02). Although not reaching the level of statistical significance, reduction in systolic blood pressure was observed with exenatide. During the openlabel extension, BMI was further reduced in those initially randomized to exenatide (cumulative BMI reduction of 4%). Conclusions and Relevance: These results provide preliminary evidence supporting the feasibility, safety, and efficacy of GLP-1 receptor agonist therapy for the treatment of severe obesity in adolescents.

UR - http://www.scopus.com/inward/record.url?scp=84876023362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876023362&partnerID=8YFLogxK

U2 - 10.1001/jamapediatrics.2013.1045

DO - 10.1001/jamapediatrics.2013.1045

M3 - Article

C2 - 23380890

AN - SCOPUS:84876023362

VL - 167

SP - 355

EP - 360

JO - JAMA Pediatrics

JF - JAMA Pediatrics

SN - 2168-6203

IS - 4

ER -